Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-l-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake
- 108 Downloads
O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) is an established positron emission tomography (PET) tracer for brain tumor imaging. This study explores the influence of dexamethasone therapy on [18F]FET uptake in the normal brain and its influence on the maximum and mean tumor-to-brain ratio (TBR).
[18F]FET PET scans of 160 brain tumor patients were evaluated (80 dexamethasone treated, 80 untreated; each group with 40 men/40 women). The standardized uptake value of [18F]FET uptake in the normal brain (SUVbrain) in the different groups was compared. Nine patients were examined repeatedly with and without dexamethasone therapy.
SUVbrain of [18F]FET uptake was significantly higher in dexamethasone-treated patients than in untreated patients (SUVbrain 1.33 ± 0.1 versus 1.06 ± 0.16 in male and 1.45 ± 0.25 versus 1.31 ± 0.28 in female patients). Similar results were observed in patients with serial PET scans. Furthermore, compared to men, a significantly higher SUVbrain was found in women, both with and without dexamethasone treatment. There were no significant differences between the different groups for TBRmax and TBRmean, which could have been masked by the high standard deviation. In a patient with a stable brain metastasis investigated twice with and without dexamethasone, the TBRmax and the biological tumor volume (BTV) decreased considerably after dexamethasone due to an increased SUVbrain.
Dexamethasone treatment appears to increase the [18F]FET uptake in the normal brain. An effect on TBRmax, TBRmean, and BTV cannot be excluded which should be considered especially for treatment monitoring and the estimation of BTV using [18F]FET PET.
Key wordsPET Brain tumors Amino acids [18F]Fluoroethyltyrosine FET Dexamethasone Tumor-to-brain ratio
The authors wish to thank Erika Wabbals, Silke Grafmüller, and Sascha Rehbein for technical assistance in radiosynthesis of [18F]FET and Silke Frensch, Suzanne Schaden, and Kornelia Frey for technical assistance in performing the PET measurements.
Compliance with Ethical Standards
The ethics committee of the University of Aachen approved the retrospective data evaluation. There was no conflict with the Declaration of Helsinki. All subjects gave prior written informed consent for the PET investigation and the use of the data for scientific evaluations.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18:1199–1208CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Kotsarini C, Griffiths PD, Wilkinson ID, Hoggard N (2010) A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: implications for physiological brain imaging of patients with intracranial tumors. Neurosurgery 67:1799–1815 discussion 1815CrossRefPubMedGoogle Scholar
- 26.Beaufrere B, Horber FF, Schwenk WF et al (1989) Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Phys 257:E712–E721Google Scholar
- 29.Varlamov O, Bethea CL, Roberts CT Jr (2014) Sex-specific differences in lipid and glucose metabolism. Front Endocrinol (Lausanne) 5:241Google Scholar